Bamco Inc. NY grew its stake in AxoGen, Inc. (NASDAQ:AXGN) by 24.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 220,969 shares of the medical equipment provider’s stock after acquiring an additional 43,034 shares during the quarter. Bamco Inc. NY owned about 0.65% of AxoGen worth $6,253,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Teacher Retirement System of Texas purchased a new position in shares of AxoGen in the 4th quarter valued at $271,000. Valeo Financial Advisors LLC purchased a new position in shares of AxoGen in the 3rd quarter valued at $244,000. OxFORD Asset Management LLP purchased a new position in shares of AxoGen in the 3rd quarter valued at $270,000. Aperio Group LLC purchased a new position in shares of AxoGen in the 4th quarter valued at $412,000. Finally, Nationwide Fund Advisors increased its holdings in shares of AxoGen by 5.5% in the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after acquiring an additional 774 shares during the period. Institutional investors and hedge funds own 67.97% of the company’s stock.
In other AxoGen news, CFO Jamie Mark Grooms sold 10,300 shares of AxoGen stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $26.21, for a total transaction of $269,963.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 169,407 shares of company stock valued at $4,593,013. 9.33% of the stock is currently owned by insiders.
AXGN stock traded down $0.35 on Monday, hitting $36.15. 340,192 shares of the company’s stock were exchanged, compared to its average volume of 353,026. AxoGen, Inc. has a 12-month low of $10.05 and a 12-month high of $40.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 4.07 and a quick ratio of 3.53. The company has a market cap of $1,259.14, a price-to-earnings ratio of -116.61 and a beta of 0.01.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. AxoGen had a negative return on equity of 70.63% and a negative net margin of 17.29%. The firm had revenue of $16.97 million for the quarter, compared to the consensus estimate of $16.38 million. During the same period in the previous year, the business earned ($0.10) EPS. The firm’s revenue for the quarter was up 48.7% on a year-over-year basis. equities research analysts anticipate that AxoGen, Inc. will post -0.3 earnings per share for the current year.
A number of research analysts have recently issued reports on AXGN shares. BidaskClub upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 23rd. Jefferies Group lifted their price target on AxoGen to $45.00 and gave the company a “buy” rating in a report on Monday, March 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of AxoGen in a report on Friday, January 5th. William Blair assumed coverage on AxoGen in a research note on Monday, February 5th. They set an “outperform” rating on the stock. Finally, JMP Securities boosted their target price on AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 1st. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. AxoGen presently has a consensus rating of “Buy” and an average target price of $33.14.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.